Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 20/20 | 0.66 |
| ▸ | TLR8 | Q9NR97 | 20/20 | 0.66 |
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929246 | 1.00 | TLR9 (0.66) | TLR9TLR8TLR7 | |
| SCHEMBL22463619 | 0.87 | TLR9 (0.64) | TLR9TLR8TLR7 | |
| SCHEMBL29928972 | 0.87 | TLR9 (0.64) | TLR9TLR8TLR7 | |
| SCHEMBL22463185 | 0.86 | TLR8 (0.59) | TLR9TLR8TLR7 | |
| SCHEMBL29928969 | 0.86 | TLR8 (0.59) | TLR9TLR8TLR7 | |
| SCHEMBL22463621 | 0.83 | TLR8 (0.58) | TLR9TLR8TLR7 | |
| SCHEMBL22463533 | 0.83 | TLR9 (0.65) | TLR9TLR8TLR7 | |
| SCHEMBL29929100 | 0.83 | TLR9 (0.65) | TLR9TLR8TLR7 | |
| SCHEMBL19951759 | 0.80 | TLR9 (1.00) | TLR9TLR8TLR7 | |
| SCHEMBL29583797 | 0.80 | TLR9 (1.00) | TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491930-B | Substituted Indole Compounds Useful as TLR Inhibitors | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | claimed |
| EP-3728225-B1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-09 | — | — | EP | claimed |
| EP-3728225-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | claimed |
| CN-111491930-A | Substituted indole compounds useful as T L R inhibitors | 百时美施贵宝公司 | 2020-08-04 | — | — | CN | claimed |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR1, TLR7, TLR9 | TLR9 3/4885TLR8 6/4885TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.